Revolutionary Results: Dermata’s Xyngari Phase 3 Trial Exceeds Expectations!
XYNGARI™ Exceeds Primary Endpoints in Phase 3 Trial
SAN DIEGO, March 26, 2025 –
Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW), a leading biotechnology company specializing in the treatment of medical skin diseases and aesthetic applications, has announced groundbreaking results from its Phase 3 trial of XYNGARI™. The once-weekly topical product candidate has demonstrated highly statistically significant and clinically meaningful improvement in the treatment of moderate-to-severe acne. With over 30 million acne patients seeking treatment in the U.S. each year, this development has the potential to revolutionize the skincare industry.
The XYNGARI™ Phase 3 trial represents a significant milestone in the treatment of acne. Not only did the product achieve its primary endpoints, but it also showed unprecedented effectiveness in improving acne symptoms. This breakthrough is a testament to Dermata’s commitment to innovation and excellence in skincare.
What sets XYNGARI™ apart is its unique formulation as the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne. Patients who participated in the trial reported remarkable improvement in their skin condition, with minimal treatment-related adverse events and no serious adverse events linked to the product.
The positive topline results from Dermata’s Phase 3 trial have set a new standard for acne treatment. With XYNGARI™ showing both efficacy and safety, patients can look forward to a cutting-edge solution for their skincare needs. The future of acne treatment is here, and it’s named XYNGARI™.
How This Breakthrough Will Impact Individuals
For individuals suffering from moderate-to-severe acne, the results of Dermata’s Phase 3 trial offer hope and relief. XYNGARI™’s effectiveness in treating acne represents a significant advancement in skincare technology, providing patients with a once-weekly topical solution that delivers visible results. By exceeding primary endpoints and demonstrating clinical benefit, XYNGARI™ has the potential to transform the lives of millions of acne patients, giving them renewed confidence and improved skin health.
How This Breakthrough Will Impact the World
The success of XYNGARI™ in Dermata’s Phase 3 trial has far-reaching implications for the skincare industry and the treatment of acne worldwide. With over 30 million acne patients seeking treatment in the U.S. each year, the introduction of a novel once-weekly topical product candidate that has achieved significant clinical benefit marks a major breakthrough in acne treatment. By setting a new standard for efficacy and safety, XYNGARI™ has the potential to revolutionize the way we approach skincare and empower individuals to take control of their skin health.
Conclusion
In conclusion, Dermata’s Phase 3 trial results for XYNGARI™ represent a game-changer in the treatment of moderate-to-severe acne. With highly statistically significant and clinically meaningful improvement demonstrated in the trial, XYNGARI™ offers a promising solution for individuals struggling with acne. As the first once-weekly topical product candidate to show such remarkable results in a Phase 3 clinical trial, XYNGARI™ has the potential to reshape the skincare industry and improve the lives of millions of acne patients worldwide.
